Populærvitenskapelig sammendrag
Children hospitalised with severe anaemia in Africa are at high risk of readmission or death within 6 months after discharge. No strategy specifically addresses this post-discharge period. We will conduct a trial to determine if 3 months of malaria chemoprevention with monthly 3-day treatment courses of the antimalarial dihydroartemisinin-piperaquine (DP) (PMC-DP) in the post-discharge management of children < 5 years of age admitted with severe anaemia is superior to the standard single 3-day treatment course with artemether-lumefantrine (AL) provided as part of standard in-hospital care around the time of discharge, giving 3 weeks prophylaxis. Design: Multi-centre, 2-arm, placebo-controlled, randomized trial in areas with moderate to intense malaria transmission Uganda and Kenya. Sample size: 2212. Primary endpoint: composite of all-cause readmissions and deaths by 6 months. Cost-effectiveness will be assessed. Results will be important to inform new WHO and national guidelines.
Vis fullstendig beskrivelse